Tina Nova

Nov 24, 2015

Veracyte said this week that it has appointed Tina Nova to its board of directors. She currently serves as president and CEO of molecular diagnostics firm Molecular Stethoscope, and she previously has served as senior VP and general manager of Illumina's oncology business unit. Nova also was a co-founder, director, president, and CEO of Genoptix Medical Laboratory, which was acquired by Novartis Pharmaceuticals in 2011. She serves on the board of directors of Arena Pharmaceuticals and is vice chairman of the board of directors for the Rady Pediatric Genomics and Systems Medicine Institute.

More Like This

Feb 16, 2018

John Goetz

John Goetz, the executive vice president and chief operating officer of Bio-Rad Laboratories, will retire and resign from his position effective March 30, 2018, but will remain available for consultation after his employment ends if a successor has not yet been named. Goetz has been with Bio-Rad for more than 40 years and was named COO in 2014. 

Feb 16, 2018

Shawn Clairmont

Codexis has appointed Shawn Clairmont senior director of molecular diagnostics. She will be responsible for commercial activities related to the firm's molecular diagnostics enzyme product line in development. Clairmont previously served as chief operating officer of BRIDGenomics. She was with Qiagen for eight years, most recently in the global advanced molecular pathology team as director of sales in America, and was also technical marketing representative and account manager at BioArray Solutions (now part of Immucor).

Feb 13, 2018

Michael Pellini

Adaptive Biotechnologies announced that former Foundation Medicine CEO Michael Pellini has joined its board. Pellini is currently chairman of Foundation Medicine's board, and is a managing partner of life science venture capital firm Section 32. He previously was president and chief operating officer of Clarient, which was acquired by GE Healthcare in 2010. He currently also serves on the boards of Tango Therapeutics, Singular Genomics, the Personalized Medicine Coalition, and the Mission Hospital Foundation. 

Feb 09, 2018

Eutillio Buccilli, Paul Kasian

Genetic Technologies, a Melbourne, Australia-based molecular diagnostics company, said this week that Eutillio Buccilli will step down as CEO. Buccilli joined the company in June 2014 as CFO and was appointed CEO in February 2015. Paul Kasian has been appointed interim CEO while the company undertakes an executive search for a permanent CEO.

Feb 07, 2018

Alberto Gutierrez

Alberto Gutierrez has joined NDA Partners as an expert consultant. The company provides consulting services in product development and regulation of medical products. Gutierrez is the former director, Office of In Vitro Diagnostics and Radiological Health, FDA Center for Devices and Radiological Health. He spent 25 years at the agency before leaving last September

Feb 05, 2018

Panna Sharma

Cancer Genetics announced that its CEO Panna Sharma will be stepping down as president, director, and CEO of the firm. The company’s board has appointed current COO John Roberts as the interim CEO. Sharma will provide consulting services during the transition period. 

Feb 02, 2018

Matthew McGrew, Daniel Comas

Danaher announced Matthew McGrew will become the firm's CFO, effective Jan. 1, 2019. He will replace Daniel Comas, who will continue as an executive vice president and a member of the Office of the Chief Executive as he begins a gradual transition to retirement. McGrew joined Danaher in 2004 as director M&A Finance. He currently is Group CFO of Danaher's Diagnostics and Dental platforms. Comas has been with Danaher since 1991 and became its CFO in 2005. 

Feb 01, 2018

Jonathan Sheldon

Qiagen has hired Jonathan Sheldon as senior vice president in charge of the company's bioinformatics business, to fill the vacancy created when Laura Furmanski left late last year. Sheldon, who also joins Qiagen's executive committee, most recently had been in charge of health sciences at Oracle. He previously started and directed the bioinformatics group at Roche (UK) Pharmaceuticals.

Jan 30, 2018

Mike Harkins, Katherine Atkinson

Edico Genome has named Mike Harkins as vice president of sales and Katherine Atkinson as VP of business development. Together, they will seek to expand the global market for the DRAGEN bio IT platform, the company said. Harkins previously led bioproduction sales at Thermo Fisher Scientific, while Atkinson most recently was commercial director of global channel partners for Illumina.

Jan 25, 2018

David Atkins

David Atkins has been named CEO of Congenica, a Cambridge, England-based maker of clinical genomics interpretation software. Atkins will lead Congenica as it looks to expand to the US and Asia, the company said. He previously served as CEO of Synevo, a chain of clinical diagnostic laboratories in Germany and Eastern Europe. With the hiring of Atkins, interim CEO Nick Lench resumes his full-time duties as chief operating officer. Cofounder and former CEO Tom Weaver remains on the Congenica board.

Jan 25, 2018

Greg Dale

LexaGene announced today that it has appointed Greg Dale as VP of product development and manufacturing. Dale previously served as VP of product development, manufacturing, and quality at Emulate. Prior to Emulate, Dale served as general manager and senior director of NGS engineering at Qiagen. 

Jan 24, 2018

Nalini Murdter

JSR Life Sciences has appointed Nalini Murdter as president and CEO of MBL International (MBLI), a JSR subdivision that provides products for life sciences research and clinical diagnostics, specializing in reagents and assays for detecting biomarkers and analyzing disease pathways. Murdter previously served as vice president of commercial operations and business development at MBLI, and managing director of the diagnostics and research products division at JSR. She was previously chief business offices a NanoString Technologies, and held several senior management positions in business development, strategy, and marketing at Agilent Technologies.

Jan 19, 2018

Tadd Lazarus

Clinical Genomics has appointed Tadd Lazarus as chief medical officer. Lazarus most recently served as senior vice president and chief medical officer for Luminex. He also served as chief medical officer and head of medical and scientific affairs, reimbursement, and public policy at Qiagen from 2013 to 2016. Lazarus also was previously employed by Gen-Probe (now Hologic) as chief medical officer and VP of clinical affairs. He began his career at Roche Diagnostics, where he held simultaneous roles in private practice and as director of medical and scientific affairs, and then as the North American medical director for the molecular diagnostics, POC, diabetes, clinical chemistry, and immunology businesses.

Jan 18, 2018

Dow Wilson

Varian Medical Systems CEO Dow Wilson has been elected to the board of Agilent Technologies, effective March 20. Wilson has been CEO of Varian Medical since 2012. Before being appointed CEO, he was the firm's chief operating officer and executive vice president. Prior to that, he was president of Varian Medical's Oncology Systems business. He previously spent 19 years at GE Healthcare and eventually became CEO of GE's Healthcare Information Technology unit. 

Jan 18, 2018

Douglas Sites

Precipio has appointed Douglas Sites to the newly created position of vice president of sales, where he will be responsible for leading sales of the firm's cancer diagnostic services to oncologists and hospitals. The company also said that it plans to triple the size of its sales force in 2018, focusing first on small to midsize oncology practices and hospitals. Sites has spent the last 20 years in life sciences and cancer diagnostics, including roles as director of sales at Plus Diagnostics and VP of sales at Asuragen. 

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.